4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 Japan
US Headquarters: 100 Tice Blvd.
398 articles with Eisai Inc.
Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisai's Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for Patients.
Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer's disease under the accelerated approval pathway
BioArctic AB's partner Eisai announced that they have completed the rolling submission to the U.S. FDA of a Biologics License Application under the accelerated approval pathway for the investigational anti-amyloid beta protofibril antibody lecanemab, for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD with confirmed presence of amyloid pathology in the brain.
Eisai and Biogen have completed the rolling submission of a Biologics License Application for lecanemab drug to the U.S. Food and Drug Administration.
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab.
A roundup of last week's top clinical trial updates and news.
Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer's dementia by several years
BioArctic AB's partner Eisai announced that an article about long-term health outcomes of the investigational anti-amyloid-beta protofibril antibody lecanemab in people living with early Alzheimer's disease, using disease modeling, was published in the peer-reviewed journal Neurology and Therapy.
New research suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab is estimated to slow the rate of disease progression in patients with Alzheimer’s Disease.
Following the decision to limit the coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, the Alzheimer’s community is now waiting for other companies to deliver new therapies.
Geisinger, Eisai team up to study use of artificial intelligence for early detection and identification of cognitive impairment that could indicate dementias, including Alzheimer's disease
Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in the detection of cognitive impairment that could identify dementias, including Alzheimer's disease (AD).
EISAI TO PRESENT DATA ON NEUROLOGY PORTFOLIO IN THE AREAS OF ALZHEIMER'S DISEASE, SLEEP AND EPILEPSY AT THE 74th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the company will present research from its robust neurology portfolio, including the findings on lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD) at the American Academy.
Biogen will await word after submitting the final study protocol for its confirmatory Phase IV ENVISION trial of Aduhelm to the U.S. Food and Drug Administration (FDA).
Lately, there has been heightened attention to briefing documents in the CNS space, a notoriously tricky area to get drugs approved, which can affect company stock prices.
Galapagos NV reports that Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced the approval by the Japanese Ministry of Health, Labour and Welfare, of a second indication for Jyseleca, a once-daily, oral, JAK1 preferentialinhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis.
Esai, Biogen, Diadem and ProMis all presented their findings on biomarker research at this year's International Conference on Alzheimer's and Parkinson's Diseases.
Latest Findings On Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship To Clinical Outcomes And Dosing Regimens - Presented At AD/PD™ 2022 Annual Meeting
Eisai Co., Ltd. and Biogen Inc. announced that the latest findings on lecanemab, an investigational anti-amyloid-beta protofibril antibody being developed for the treatment of early Alzheimer's disease, were presented at the Aβ Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases March 15-20 in Barcelona, Spain and virtually.
The data showed mixed end results, but the diagnostics involved in treating Alzheimer’s were the star of the conference.
Biogen reported new data from a long-term extension phase of the Phase III clinical studies of Aduhelm (aducanumab) for Alzheimer’s disease.
Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).
Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting
Eisai Co., Ltd. announced the company will present research from its robust Alzheimer's disease pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta protofibril antibody for the treatment of early AD, at the AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's Diseases from March 15-20 in Barcelona, Spain and virtually.
It's not clear if the recent deaths reported in FAERS resulted from the patients taking Aduhelm. This article takes a deep dive into this controversy.